Tarsier Pharma's clinical-stage status as an ocular biotech with no approved products and trailing twelve-month net losses of $5.07 million has kept the IPO window closed, driving the 98.6% market-implied probability of no closing before September 2026. The company filed an F-1 in April 2026, set terms in May for a $45 million raise at an $8–10 share price range implying roughly $250–300 million post-IPO equity value, and later upsized modestly, yet execution stalled amid subdued risk appetite for pre-revenue issuers and the need to advance its SPA-backed Phase 3 program. This consensus reflects aggregated trader positioning on persistent financing headwinds for small-cap biotechs. A successful roadshow completion, improved sector sentiment, or positive regulatory or trial updates could still reopen the window before September.
Експериментальне резюме, згенероване ШІ з посиланням на дані Polymarket. Це не торгова порада і не впливає на вирішення цього ринку. · ОновленоNo IPO before September 2026 98.6%
$400M-$450M 3.1%
$250M-$300M 3.0%
$350M-$400M 1.9%
$15,112 Обс.
$15,112 Обс.
Jul 9, 2026
<$250M
2%
$250M-$300M
3%
$300M-$350M
<1%
$350M-$400M
2%
$400M-$450M
3%
>$450M
<1%
No IPO before September 2026
99%
No IPO before September 2026 98.6%
$400M-$450M 3.1%
$250M-$300M 3.0%
$350M-$400M 1.9%
$15,112 Обс.
$15,112 Обс.
Jul 9, 2026
<$250M
$907 Обс.
2%
$250M-$300M
$979 Обс.
3%
$300M-$350M
$561 Обс.
<1%
$350M-$400M
$561 Обс.
2%
$400M-$450M
$349 Обс.
3%
>$450M
$680 Обс.
<1%
No IPO before September 2026
$11,075 Обс.
99%
This market will resolve based on Tarsier Pharma's market capitalization at the closing price on its first day of trading.
As of market creation, the IPO is scheduled to price on July 9 (ET). If no such IPO occurs by August 31, 2026, 11:59 PM ET, the market will resolve to "No IPO before September 2026".
Market capitalization expresses the monetary value of a company’s outstanding shares, stated in its pricing currency.
It is calculated as the total number of outstanding shares, multiplied by the official closing share price of the publicly traded class on the first trading day.
If necessary, to accurately capture the company’s total market capitalization, rather than a stock-class-specific market capitalization, the calculation will include all outstanding share classes and apply any stated conversion ratios to the publicly traded class. Where no conversion right exists, such shares will be counted at their stated outstanding amount without discount, unless official filings explicitly specify differently.
The number of outstanding shares will be determined from official company filings or disclosures (e.g., SEC filings). The closing share price on the first trading day will be determined from the primary exchange’s official listing page.
If the relevant value falls exactly between two brackets, this market will resolve to the higher range bracket.
The primary resolution source for this market will be official company filings and the primary exchange’s official listing page. The market capitalization will be determined through appropriate calculation using the total outstanding shares and the closing price from the first day of trading.
In the event of an interruption in the normal trading session on the specified company’s first day of trading (e.g., a circuit breaker or half-day), the market will resolve according to the official closing price of the abbreviated session. If no such official closing price is published, the market will resolve according to the next trading day on which an official closing price is published, treating that day as the first day of trading for the purposes of this market.Tarsier Pharma's clinical-stage status as an ocular biotech with no approved products and trailing twelve-month net losses of $5.07 million has kept the IPO window closed, driving the 98.6% market-implied probability of no closing before September 2026. The company filed an F-1 in April 2026, set terms in May for a $45 million raise at an $8–10 share price range implying roughly $250–300 million post-IPO equity value, and later upsized modestly, yet execution stalled amid subdued risk appetite for pre-revenue issuers and the need to advance its SPA-backed Phase 3 program. This consensus reflects aggregated trader positioning on persistent financing headwinds for small-cap biotechs. A successful roadshow completion, improved sector sentiment, or positive regulatory or trial updates could still reopen the window before September.
This market will resolve based on Tarsier Pharma's market capitalization at the closing price on its first day of trading.
As of market creation, the IPO is scheduled to price on July 9 (ET). If no such IPO occurs by August 31, 2026, 11:59 PM ET, the market will resolve to "No IPO before September 2026".
Market capitalization expresses the monetary value of a company’s outstanding shares, stated in its pricing currency.
It is calculated as the total number of outstanding shares, multiplied by the official closing share price of the publicly traded class on the first trading day.
If necessary, to accurately capture the company’s total market capitalization, rather than a stock-class-specific market capitalization, the calculation will include all outstanding share classes and apply any stated conversion ratios to the publicly traded class. Where no conversion right exists, such shares will be counted at their stated outstanding amount without discount, unless official filings explicitly specify differently.
The number of outstanding shares will be determined from official company filings or disclosures (e.g., SEC filings). The closing share price on the first trading day will be determined from the primary exchange’s official listing page.
If the relevant value falls exactly between two brackets, this market will resolve to the higher range bracket.
The primary resolution source for this market will be official company filings and the primary exchange’s official listing page. The market capitalization will be determined through appropriate calculation using the total outstanding shares and the closing price from the first day of trading.
In the event of an interruption in the normal trading session on the specified company’s first day of trading (e.g., a circuit breaker or half-day), the market will resolve according to the official closing price of the abbreviated session. If no such official closing price is published, the market will resolve according to the next trading day on which an official closing price is published, treating that day as the first day of trading for the purposes of this market.
As of market creation, the IPO is scheduled to price on July 9 (ET). If no such IPO occurs by August 31, 2026, 11:59 PM ET, the market will resolve to "No IPO before September 2026".
Market capitalization expresses the monetary value of a company’s outstanding shares, stated in its pricing currency.
It is calculated as the total number of outstanding shares, multiplied by the official closing share price of the publicly traded class on the first trading day.
If necessary, to accurately capture the company’s total market capitalization, rather than a stock-class-specific market capitalization, the calculation will include all outstanding share classes and apply any stated conversion ratios to the publicly traded class. Where no conversion right exists, such shares will be counted at their stated outstanding amount without discount, unless official filings explicitly specify differently.
The number of outstanding shares will be determined from official company filings or disclosures (e.g., SEC filings). The closing share price on the first trading day will be determined from the primary exchange’s official listing page.
If the relevant value falls exactly between two brackets, this market will resolve to the higher range bracket.
The primary resolution source for this market will be official company filings and the primary exchange’s official listing page. The market capitalization will be determined through appropriate calculation using the total outstanding shares and the closing price from the first day of trading.
In the event of an interruption in the normal trading session on the specified company’s first day of trading (e.g., a circuit breaker or half-day), the market will resolve according to the official closing price of the abbreviated session. If no such official closing price is published, the market will resolve according to the next trading day on which an official closing price is published, treating that day as the first day of trading for the purposes of this market.
Ринок відкрито: Jul 7, 2026, 9:12 AM ET
Обсяг
$15,112Дата завершення
Jul 9, 2026Ринок відкрито
Jul 7, 2026, 9:12 AM ETResolver
0x69c47De9D...This market will resolve based on Tarsier Pharma's market capitalization at the closing price on its first day of trading.
As of market creation, the IPO is scheduled to price on July 9 (ET). If no such IPO occurs by August 31, 2026, 11:59 PM ET, the market will resolve to "No IPO before September 2026".
Market capitalization expresses the monetary value of a company’s outstanding shares, stated in its pricing currency.
It is calculated as the total number of outstanding shares, multiplied by the official closing share price of the publicly traded class on the first trading day.
If necessary, to accurately capture the company’s total market capitalization, rather than a stock-class-specific market capitalization, the calculation will include all outstanding share classes and apply any stated conversion ratios to the publicly traded class. Where no conversion right exists, such shares will be counted at their stated outstanding amount without discount, unless official filings explicitly specify differently.
The number of outstanding shares will be determined from official company filings or disclosures (e.g., SEC filings). The closing share price on the first trading day will be determined from the primary exchange’s official listing page.
If the relevant value falls exactly between two brackets, this market will resolve to the higher range bracket.
The primary resolution source for this market will be official company filings and the primary exchange’s official listing page. The market capitalization will be determined through appropriate calculation using the total outstanding shares and the closing price from the first day of trading.
In the event of an interruption in the normal trading session on the specified company’s first day of trading (e.g., a circuit breaker or half-day), the market will resolve according to the official closing price of the abbreviated session. If no such official closing price is published, the market will resolve according to the next trading day on which an official closing price is published, treating that day as the first day of trading for the purposes of this market.Tarsier Pharma's clinical-stage status as an ocular biotech with no approved products and trailing twelve-month net losses of $5.07 million has kept the IPO window closed, driving the 98.6% market-implied probability of no closing before September 2026. The company filed an F-1 in April 2026, set terms in May for a $45 million raise at an $8–10 share price range implying roughly $250–300 million post-IPO equity value, and later upsized modestly, yet execution stalled amid subdued risk appetite for pre-revenue issuers and the need to advance its SPA-backed Phase 3 program. This consensus reflects aggregated trader positioning on persistent financing headwinds for small-cap biotechs. A successful roadshow completion, improved sector sentiment, or positive regulatory or trial updates could still reopen the window before September.
This market will resolve based on Tarsier Pharma's market capitalization at the closing price on its first day of trading.
As of market creation, the IPO is scheduled to price on July 9 (ET). If no such IPO occurs by August 31, 2026, 11:59 PM ET, the market will resolve to "No IPO before September 2026".
Market capitalization expresses the monetary value of a company’s outstanding shares, stated in its pricing currency.
It is calculated as the total number of outstanding shares, multiplied by the official closing share price of the publicly traded class on the first trading day.
If necessary, to accurately capture the company’s total market capitalization, rather than a stock-class-specific market capitalization, the calculation will include all outstanding share classes and apply any stated conversion ratios to the publicly traded class. Where no conversion right exists, such shares will be counted at their stated outstanding amount without discount, unless official filings explicitly specify differently.
The number of outstanding shares will be determined from official company filings or disclosures (e.g., SEC filings). The closing share price on the first trading day will be determined from the primary exchange’s official listing page.
If the relevant value falls exactly between two brackets, this market will resolve to the higher range bracket.
The primary resolution source for this market will be official company filings and the primary exchange’s official listing page. The market capitalization will be determined through appropriate calculation using the total outstanding shares and the closing price from the first day of trading.
In the event of an interruption in the normal trading session on the specified company’s first day of trading (e.g., a circuit breaker or half-day), the market will resolve according to the official closing price of the abbreviated session. If no such official closing price is published, the market will resolve according to the next trading day on which an official closing price is published, treating that day as the first day of trading for the purposes of this market.
As of market creation, the IPO is scheduled to price on July 9 (ET). If no such IPO occurs by August 31, 2026, 11:59 PM ET, the market will resolve to "No IPO before September 2026".
Market capitalization expresses the monetary value of a company’s outstanding shares, stated in its pricing currency.
It is calculated as the total number of outstanding shares, multiplied by the official closing share price of the publicly traded class on the first trading day.
If necessary, to accurately capture the company’s total market capitalization, rather than a stock-class-specific market capitalization, the calculation will include all outstanding share classes and apply any stated conversion ratios to the publicly traded class. Where no conversion right exists, such shares will be counted at their stated outstanding amount without discount, unless official filings explicitly specify differently.
The number of outstanding shares will be determined from official company filings or disclosures (e.g., SEC filings). The closing share price on the first trading day will be determined from the primary exchange’s official listing page.
If the relevant value falls exactly between two brackets, this market will resolve to the higher range bracket.
The primary resolution source for this market will be official company filings and the primary exchange’s official listing page. The market capitalization will be determined through appropriate calculation using the total outstanding shares and the closing price from the first day of trading.
In the event of an interruption in the normal trading session on the specified company’s first day of trading (e.g., a circuit breaker or half-day), the market will resolve according to the official closing price of the abbreviated session. If no such official closing price is published, the market will resolve according to the next trading day on which an official closing price is published, treating that day as the first day of trading for the purposes of this market.
Обсяг
$15,112Дата завершення
Jul 9, 2026Ринок відкрито
Jul 7, 2026, 9:12 AM ETResolver
0x69c47De9D...Tarsier Pharma's clinical-stage status as an ocular biotech with no approved products and trailing twelve-month net losses of $5.07 million has kept the IPO window closed, driving the 98.6% market-implied probability of no closing before September 2026. The company filed an F-1 in April 2026, set terms in May for a $45 million raise at an $8–10 share price range implying roughly $250–300 million post-IPO equity value, and later upsized modestly, yet execution stalled amid subdued risk appetite for pre-revenue issuers and the need to advance its SPA-backed Phase 3 program. This consensus reflects aggregated trader positioning on persistent financing headwinds for small-cap biotechs. A successful roadshow completion, improved sector sentiment, or positive regulatory or trial updates could still reopen the window before September.
Експериментальне резюме, згенероване ШІ з посиланням на дані Polymarket. Це не торгова порада і не впливає на вирішення цього ринку. · Оновлено
Обережно з зовнішніми посиланнями.
Обережно з зовнішніми посиланнями.
Часті запитання